An overall trend in decreased STAT3 expression was consistently observed, regardless of whether patients received danvatirsen alone or in combination with durvalumab.
← all excerpts
Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.
1
—
—